The identification of immune checkpoint molecules, such as programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), has made immunotherapy one of the most promising curative modalities for lung cancer in recent years. This evidence concerns the gene CTLA4 and lung carcinoma.